About 200 reports

  • IMPORTANT INDICATIONS FOR ONCOLOGY BIOSIMILARS
  • Supportive Care in Oncology

Colorectal Cancer: Competitive Landscape to 2026, April 2018, GDHC##CL GlobalData (2017).

  • Lymphoma
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.

Keytruda

8770 10000 7800

The interaction between PD-## and its primary ligand, PD-L##, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells.

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • United States
  • PSMA ADC
  • HAEMATOLOGICAL CANCER

COLORECTAL CANCER ##. ##. ##. ##.

  • Lymphoma
  • North America
  • United States
  • Market Size
  • Seattle Genetics, Inc.
  • Phase of Development
  • CERVICAL CANCER

IN A STUDY THAT EVALUATED HER##/ NEU CAR-T CELLS IN PATIENTS WITH COLORECTAL CANCER, DEATH OF ONE PATIENT WAS REPORTED FIVE DAYS AFTER THE INFUSION OF T-CELLS.

  • Lymphoma
  • Company
  • Market Size
  • Juno Therapeutics Inc.
  • Novartis AG
  • ABBREVIATIONS

Clinical Targets Being Investigated for CAR Cell Therapies in Solid Tumors by Organ Group KEY TARGETS ARE EMERGING FOR CERTAIN CANCER TYPES, WITH IMPORTANT TARGETS IN OTHER CANCERS NOT SO WELL DEFINED EPCAM CD## Mesothelin Multiple PSMA FOLR## MET MUC## DLLR## PMEL Source: GlobalDat

  • Lymphoma
  • United States
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

AVASTIN IS MOST NOTABLY APPROVED FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER.

  • Lymphoma
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • Type of Therapy
  • Phase I/II

ADDITIONALLY, THE DRUG IS BEING EVALUATED FOR COLORECTAL CANCER IN PHASE II; HOWEVER, THERE ARE NO RECENT UPDATES ON ITS DEVELOPMENT.

  • Lymphoma
  • North America
  • United States
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • XENCOR
  • GLOSSARY

THE DRUG TARGETS THE MUTATED EGFR GENE IN PATIENTS WITH NSCLC, METASTATIC COLORECTAL CANCER, GASTRIC CANCER, RENAL CANCER AND SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SCCHN).

  • Lymphoma
  • North America
  • United States
  • MedImmune, LLC
  • Roche Group
  • 3.1 THE U.S.

For example, HER## is a receptor is a overexpressed in several cancers (some breast or colorectal cancer subtypes).

  • Lymphoma
  • Medical Biotechnology
  • World
  • Forecast
  • Celgene Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2018
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

SMALL MOLECULES TO INHIBIT HDAC## FOR COLORECTAL CANCER - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Taipei Medical University NA NA Small Molecules to Inhibit HDAC## for Colorectal Cancer Small m

  • Cancer
  • Lymphoma
  • United States
  • World
  • Product Initiative

IN A STUDY EVALUATING HER##/ NEU CAR-T CELLS IN PATIENTS WITH COLORECTAL CANCER, DEATH OF ONE PATIENT WAS REPORTED FIVE DAYS AFTER THE INFUSION OF T CELLS.

  • Lymphoma
  • North America
  • United States
  • Amgen Inc.
  • MedImmune, LLC
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018
  • DORMANT PRODUCTS, H1 2018 (CONTD..2), H1 2018

As of March 2012, it was in Phase II for metastatic colorectal cancer and as of January 2010, it was in Phase II for breast cancer (first line).

  • Lymphoma
  • Oncology
  • United States
  • World
  • Acetylon Pharmaceuticals, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2018 (CONTD..1), H2 2018
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

Two patients with PI##KCA H##R mutant breast cancers have ongoing RECIST partial response; ## patient with PIK##CA E##K colorectal cancer had stable disease for ## weeks.

  • Lymphoma
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • PIPELINE BY ABBVIE INC, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

THE PHASE ## TRIAL IN COLORECTAL CANCER IS ONGOING, WITH A PRESENTATION OF THE RESULTS ANTICIPATED ON NOVEMBER ## AT THE 2005 EUROPEAN CANCER CONFERENCE (ECCO).

  • Hospital
  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • GlaxoSmithKline plc

The American Cancer Society estimates ##, ## new cases of colorectal cancer will be diagnosed in the U. S. in 2017, and expects colorectal cancer to cause over ##, ## deaths in 2017.

  • Breast Cancer
  • Lymphoma
  • United States
  • Company Financials
  • Seattle Genetics, Inc.

It also helps in monitoring cancer treatment and stages, particularly colorectal cancer, Hodgkin' s disease, non-Hodgkin' s lymphoma, melanoma, breast cancer, and lung cancer. ##. ##. ##. ## F l u o r i n e - ## ## TABLE ## Florbetapir F-##

  • Lymphoma
  • Europe
  • World
  • Market Size
  • Bayer AG
  • adenocarcinoma of pancreas. The trial was registered with the U.S. National Institutes of Health.
  • Cell Non-Hodgkin Lymphoma. The trial is registered with U.S. National Institutes of Health.

NA : Not Available Source: Global Markets Direct SHR-## - DRUG PROFILE cancer patient (##/ ##), one hepatocellular carcinoma patient (##/ ##), one colorectal carcinoma patient (##/ ##), and one bladder cancer pa

  • Hepatitis
  • Lymphoma
  • Therapy
  • United States
  • Company Operations
  • CS-2164 - DRUG PROFILE
  • AVELUMAB - DRUG PROFILE

It was also under development for colorectal cancer.

  • Lymphoma
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Merck & Co., Inc.
  • PIPELINE BY BAYER AG, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..1), H1 2018

In part A, a pt with ATM loss colorectal cancer had RECIST complete response (## months+) and ## pts had RECIST stable disease (SD).

  • Cancer
  • Lymphoma
  • Therapy
  • World
  • Product Initiative
  • KLA-167 - DRUG PROFILE
  • CXD-101 - DRUG PROFILE

Eighteen patients had partial response, including ## esophageal squamous cell carcinoma patients (##/ ##), three gastric cancer patients (##/ ##), one lung cancer patient (##/ ##), one nasopharynx cancer patient (##/ ##),

  • Cancer
  • Immunotherapy
  • Lymphoma
  • United States
  • Product Initiative
  • PIPELINE BY CHODANG PHARM CO LTD, H2 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018 (CONTD..1), H2 2018

Sub-category: Thymic Malignancies Category: Lung Cancer - Non-Small Cell Local-regional/ Small Cell/ Other Thoracic Cancers Session: Lung Cancer - Non-small Cell Local-regional/ Small Cell/ Other Thoracic Cancers Meeting: 2014 ASCO Annual Meeting A

  • Leukemia
  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Metastatic Adenocarcinoma of The Pancreas
  • entinostat

As of March 2012, it was in Phase II for metastatic colorectal cancer and as of January 2010, it was in Phase II for breast cancer (first line).

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Syndax Pharmaceuticals, Inc.

BODY MASS INDEX AND RISK OF COLORECTAL CANCER IN WOMEN (UNITED STATES).

  • Lymphoma
  • Affimed Therapeutics AG
  • Incyte Corporation
  • Merck & Co., Inc.
  • Seattle Genetics, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2018
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

The drug candidate is in preclinical stage of development for the treatment of head and neck cancer, pancreatic cancer, prostate cancer, ovarian cancer, colorectal cancer and malignant mesothelioma in the United States.

  • Immunotherapy
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Immunovaccine Inc.
  • Product Profile - Opdivo

CANCER; ##(##): ##- ##.

  • Lymphoma
  • United States
  • AbbVie Inc.
  • Novartis AG
  • Roche Group
  • Refractory Chronic Lymphocytic Leukemia (CLL)
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018

Sub-category: Thymic Malignancies Category: Lung Cancer - Non-Small Cell Local-regional/ Small Cell/ Other Thoracic Cancers Session: Lung Cancer - Non-small Cell Local-regional/ Small Cell/ Other Thoracic Cancers Time ##: Sunday June

  • Leukemia
  • Lymphoma
  • United States
  • World
  • Product Initiative
  • PIPELINE BY BRISTOL-MYERS SQUIBB CO, H2 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2018 (CONTD..1), H2 2018

One non-small cell lung cancer (NSCLC) patient and one squamous cell carcinoma of the head and neck (SCCHN) patient had an objective response.

  • Immunotherapy
  • Lymphoma
  • Research And Development
  • Therapy
  • Juno Therapeutics Inc.
  • PERIPHERAL T-CELL LYMPHOMAS (PTCL)
  • JAPAN TOBACCO INC

IT WAS ALSO UNDER DEVELOPMENT FOR EARLY MYELOFIBROSIS, METASTATIC PROSTATE CANCER, PLAQUE PSORIASIS, ALOPECIA AREATA, RHEUMATOID ARTHRITIS, METASTATIC COLORECTAL CANCER AND METASTATIC ADENOCARCINOMA OF THE PANCREAS, NON-SMALL CELL LUNG CANCER, METASTATIC BREAST

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Incyte Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018 (CONTD..1), H1 2018
  • PIPELINE BY BRISTOL-MYERS SQUIBB CO, H1 2018

IT ACT BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##) EXPRESSING CANCER CELLS.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Juno Therapeutics Inc.
  • COLORECTAL CANCER
  • PIPELINE BY FORTY SEVEN INC, H1 2018

THE THERAPEUTIC CANDIDATE IS IN PHASE I/ II STAGE OF DEVELOPMENT FOR RELAPSED AND REFRACTORY B-CELL NON-HODGKIN' S LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, INDOLENT LYMPHOMA, MARGINAL ZONE, FOLLICULAR LYMPHOMA AND PANCREATIC DUCTAL ADENOCARCINOMA, HEAD AND NECK CANCER, BREAST AND OV

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • TTI